

Elevator Pitch: Amplio Pharma

Name Start-up Company : Amplio Pharma

Name (co-)Founder: Marguerite Mensonides, PhD

Mission Statement: Address significant efficacy gaps in existing treatments by developing innovative solutions



About Us:

Amplio Pharma, established in 2021 in Sweden and now based in Leiden, Netherlands, is focused on developing value-added medicines for broad patient populations. With a team of pharmaceutical industry veterans, our mission is to address significant efficacy gaps in existing treatments by developing innovative solutions. We recently completed preclinical development of our lead pipeline candidate, NovoBioJect, which is poised to enter clinical trials.

Problem aiming to solve:

Autoimmune diseases, or immune-mediated inflammatory diseases (IMiDs), are a global health burden, affecting around 10% of the population. These chronic conditions, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease, cause debilitating pain, fatigue, and early mortality due to organ damage. Existing first-line treatments, such as methotrexate, are often ineffective in controlling disease flares in about two-thirds of patients. As a result, patients require additional, expensive therapies like biologics and JAK inhibitors, leading to an annual treatment cost of €25 billion in the U.S. and Europe alone. Methotrexate's limited efficacy is largely due to its rapid elimination from disease-driving cells.

Our Solution:

Amplio Pharma is developing NovoBioJect, a novel treatment based on our proprietary NovoBioMed technology. This treatment delivers methotrexate along with a pharmacokinetic (PK) enhancer in a once-weekly subcutaneous injection. The PK enhancer helps retain methotrexate within disease-driving cells for a longer duration, improving disease control with fewer side effects and enhancing efficacy in a broader range of patients.

USP:

NovoBioJect is the first disease-modifying antirheumatic drug (DMARD) to incorporate a PK enhancer, with granted patent protection until mid-2037. By improving the efficacy of methotrexate, NovoBioJect may reduce or eliminate the need for biologics and JAK inhibitors.

Seeking:

We are currently raising funds in our Seed Round (minimum ticket size €300k) and welcome discussions with experts in PK enhancers or drug development.

Start-up & Scale-up *NEWS*

Phlox Therapeutics secures €1.9M to advance RNA therapies for Cardiomyopathies.

RIBOPRO has successfully secured Series A funding, marking a significant milestone in their journey to revolutionize mRNA-based technologies.

iProtics, a spin-off from Leiden University, has secured its first investment, receiving €350,000 from UNIQ - Finance for the Future the Zuid-Holland innovation fund.

Kaminari Medical, has secured €3.8M in a fresh funding round. Additionally, an Innovation Credit of €1.5M from the Netherlands Enterprise Agency (RVO) has been secured.

NOVAMEAT secured a €17.4m Series A financing round, co-lead by Forbion, alongside Sofinnova Partners, Unovis Asset Management, Praesidium and Rubio Impact Ventures.

Spatium Medical raised EUR 5 million to bring smart insufflation technology to operating rooms in Europe and the US

XS Innovations successfully raised EUR 1.1 million in seed funding to accelerate the development of our cutting-edge vascular access device, the Dynamic AVF.

Confo Therapeutics announced EUR 60M Series B Financing to advance pipeline of novel GPCR-Modulating Therapies into Clinical Development

AstriVax has entered clinical phase with its novel vaccine platform technology.

Rarity Bioscience, a pioneering molecular biotech company, announces the successful closure of a €6.5 million funding round.

Augustine Therapeutics raised EUR 17 million in a Series A first closing to advance lead candidate into clinical development in neurological diseases

UPyTher raised seed financing to advance the development of its lead product UPT-211 for treatment of peritoneal cancer of colorectal cancer origin.

Heb je ook start-up & scale-up nieuws om te delen, stuur ons een mail naar: biotechnews@hyphenprojects.nl